Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Market Closed - Toronto S.E.
Other stock markets
 16:00:00 2024-06-11 EDT 		5-day change 1st Jan Change
3.69 CAD +0.27% Intraday chart for Eupraxia Pharmaceuticals Inc. +0.14% -31.28%
06-05 Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 MT
05-23 Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis MT

Insiders

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Eupraxia Pharmaceuticals Forms Gastrointestinal Clinical Advisory Board
MT
Eupraxia Pharmaceuticals Inc. Appoints Mark Kowalski as Chief Medical Officer
CI
Eupraxia Pharmaceuticals Inc. Brief: Appointing Mark Kowalski, MD, PhD, as Company's Chief Medical Officer, effective May 18, 2023
MT
Eupraxia Pharmaceuticals Inc. Appoints Industry Veteran, Paul Brennan, As Chief Business Officer
MT
Eupraxia Pharmaceuticals Appoints Paul Brennan to Chief Business Officer
CI
Eupraxia Pharmaceuticals Inc. Elects Richard M. Glickman to Board of Directors
CI
Eupraxia Pharmaceuticals : Names New CFO
MT
Eupraxia Pharmaceuticals Inc. Appoints Bruce Cousins as New President, Effective May 3, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EPRX Stock
  4. News Eupraxia Pharmaceuticals Inc.
  5. Insiders